YOUR FAMMED FORUM CME TRANSCRIPT

You may follow your progress here. Each time you complete a session evaluation, it will be recorded in the transcript below with the corresponding CME credit.

Only courses completed during the 2023 FamMed Forum will reflect CME credit below on your transcript. If you completed a session evaluation and do not see it listed below, please go back to the evaluations page and resubmit it.

NOTE: If your name below is incorrect or is missing your professional credentials, please click the GREEN Edit Your Profile button now and correct it.

AT THE END OF THE CONFERENCE - PLEASE PRINT OUT YOUR TRANSCRIPT AND KEEP IT FOR REPORTING TO AAFP.

If you have questions or need help, please email us!

Edit Your Profile

ACCREDITATION

The AAFP has reviewed 2023 FamMed Forum, and deemed it acceptable for AAFP credit. Term of approval is from 05/05/2023 to 05/07/2023. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

AAFP Prescribed credit is accepted by the American Medical Association as equivalent to AMA PRA Category 1 credit(s)™ toward the AMA Physician's Recognition Award. When applying for the AMA PRA, Prescribed credit earned must be reported as Prescribed, not as Category 1.

DISCLOSURES

None of the planners for this educational activity have relevant financial relationship(s) to disclose with ineligible companies whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

Dr. Kim Yu, Dr. Jeff Levine, Dr. Everett Schlam, Dr. Sajina Prabhakaran, Dr. Jeff Zlotnick, Dr. David Cennimo, Dr. Bradford Bobrin, Dr. Tony Juneja, and John Hunt, faculty for this educational event, have no relevant financial relationship(s) with ineligible companies to disclose.

Dr. Scott Wright, faculty for this educational event, is a speaker and advisor for Novartis, Boehringer Ingelheim.

Dr. Domenica M. Rubino, faculty for this educational event, is a consultant, advisor and speaker for Novo Nordisk-Investigator, a consultant and advisor for Boehringer Ingelheim-investigator, and a consultant for Kayentis.

All of the relevant financial relationships listed for these individuals have been mitigated.